# A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer

Source: https://onco.cc/trials/nct06431490/  
OnCo record `nct06431490` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of TQB2102 in biliary tract cancer, run by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., now recruiting.

## Summary

A Study of TQB2102 for Injection in the Treatment of HER2-positive Biliary Tract Cancer is a phase 1/2 interventional study registered as NCT06431490 by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., with 102 participants planned, started 2024-07-22 and due to reach its primary completion in 2027-05. Interventions recorded: TQB2102 for injection.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06431490
- Phase: 1/2
- Setting: A Study to Evaluate the Efficacy, Safety, and Immunogenicity of TQB2102 for Injection in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer
- Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- Enrolled: 102

## Sources

- ClinicalTrials.gov NCT06431490: https://clinicaltrials.gov/study/NCT06431490

## Connected records

- cancers: [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/)
- drugs: [TQB2102](https://onco.cc/drugs/tqb2102/)
- companies: [Sino Biopharmaceutical (Chia Tai Tianqing)](https://onco.cc/companies/sino-biopharm/)

---
JSON: https://onco.cc/api/v1/entities/nct06431490.json